Presentation and Outcomes of Patients with ESKD and COVID-19

作者：Anthony M. Valeri, Shelief Y. Robbins-Juarez, Jacob S. Stevens, Wooin Ahn, Maya K. Rao, Jai Radhakrishnan, Ali G. Gharavi, Sumit Mohan, Syed Ali Husain · 发表于：Journal of the American Society of Nephrology · 年份：2020 · DOI：10.1681/asn.2020040470 · 被引用次数：373 · 研究领域：COVID-19 Clinical Research Studies、Muscle and Compartmental Disorders、Acute Kidney Injury Research

Significance Statement Immunosuppression and a high prevalence of comorbidities among patients with ESKD on dialysis raise concerns that such patients may have an elevated risk of severe coronavirus disease 2019 (COVID-19). However, the outcomes for COVID-19 in this patient population are not clear. In their study of 59 patients with ESKD and COVID-19 receiving dialysis at a New York City medical center, the authors found that although the presentation of patients on dialysis with COVID-19 was similar to that of the general population, these patients have poor outcomes, including 31% overall mortality and 75% mortality among those requiring mechanical ventilation. In addition, higher levels of inflammatory markers associated with severe disease. This information will help inform care of patients on dialysis who develop COVID-19 and reinforces the importance of infection control measures when treating this vulnerable population. Background The relative immunosuppression and high prevalence of comorbidities in patients with ESKD on dialysis raise concerns that they may have an elevated risk of severe coronavirus disease 2019 (COVID-19), but outcomes for COVID-19 in such patients are unclear. Methods To examine presentation and outcomes of COVID-19 in patients with ESKD on dialysis, we retrospectively collected clinical data on 59 patients on dialysis who were hospitalized with COVID-19. We used Wilcoxon rank sum and Fischer exact tests to compare patients who died versus those ...